# Imjudo (tremelimumab-actl) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tremelimumab-actl

> The FDA approved Imjudo (tremelimumab-actl), sponsored by ASTRAZENECA PLC (AZN), on November 10, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Imjudo (tremelimumab-actl) |
| Codes |  |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | To treat unresectable hepatocellular carcinoma |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### October 21, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat unresectable hepatocellular carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Imjudo | tremelimumab | 10/21/2022 | To treat unresectable hepatocellular carcinomaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "BLA761289 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20221021, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product IMJUDO (TREMELIMUMAB-ACTL)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761289%22

### November 10, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761270 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20221110, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product IMJUDO (TREMELIMUMAB-ACTL)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761270%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tremelimumab-actl.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Imjudo (tremelimumab-actl) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tremelimumab-actl

```bibtex
@misc{secapidev_pdufa_tremelimumab_actl_20261116,
  title        = {Imjudo (tremelimumab-actl) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tremelimumab-actl}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tremelimumab_actl_20261116","title":"Imjudo (tremelimumab-actl) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tremelimumab-actl","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
